EY said AI-driven supply chain orchestration could address persistent clinical trial distribution and complexity challenges, especially for advanced modalities such as monoclonal antibodies and cell and gene therapies. In its analysis, the consultancy argued that many supply failures originate earlier in study design and planning, then amplify during start-up. EY cited impacts including higher costs, drug waste, delays, and patient dosing failures tied to insufficient handling of demand variability and protocol-driven complexities like labeling strategy constraints. The report recommended shifting from manual, reactive logistics to automated, predictive digital supply chain systems. For trial sponsors, the message is that AI tools may become a core capability for meeting decentralized-study demands and tightening global regulatory requirements.